論文・技術情報追加のお知らせ

1. Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database.

ICIとターゲット療法併用が肝炎リスク増加

対象DB：FAERS

2. Safety assessment of cabozantinib in patients with renal cell carcinoma: retrospective pharmacovigilance study based on FAERS database.

カボザンチニブの副作用に関する新たな解析結果

対象DB：FAERS

3. Real-world research on beta-blocker usage trends in China and safety exploration based on the FDA Adverse Event Reporting System (FAERS).

中国でのベータブロッカー使用と新たな副作用発見

対象DB：FAERS

4. Mapping global public perspectives on mRNA vaccines and therapeutics.

mRNAワクチンに対する否定的な感情と信頼不足

対象DB：FAERS,VAERS

5. Progressive multifocal leukoencephalopathy associated with sphingosine-1-phosphate receptor modulators: A large case series.

S1PR薬剤によるPMLのリスク因子を解析

対象DB：FAERS

6. Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system.

ICIsによるSCLC患者の免疫関連副作用解析

対象DB：FAERS

7. Safety profiles of intravesical Bacillus Calmette-Guerin in bladder cancer.

BCG治療の性差と副作用リスクを解析

対象DB：FAERS,VAERS

8. Cyclin-dependent kinase 4/6 inhibitors and cardiotoxic events in breast cancer: A pharmacovigilance study based on the FAERS database.

リボシクリブの心毒性と薬剤相互作用を分析

対象DB：FAERS

9. Adverse events associated with oseltamivir and baloxavir marboxil in against influenza virus therapy: A pharmacovigilance study using the FAERS database.

オセルタミビルとバロキサビルの副作用を分析

対象DB：FAERS

10. Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS).

サプロプテリンの副作用を実世界データで分析

対象DB：FAERS

11. Quantitative Structure-Activity Relationship Models to Predict Cardiac Adverse Effects.

新しいモデルで薬剤の心毒性を迅速予測

対象DB：FAERS

12. Disseminated intravascular coagulation is an underestimated but fatal adverse event associated with blinatumomab therapy: A pharmacovigilance analysis of FAERS.

ブリナツモマブ治療でまれな血液系副作用が致命的な場合あり

対象DB：FAERS

13. Investigating the Safety Profile of Fast-Track COVID-19 Drugs Using the FDA Adverse Event Reporting System Database: A Comparative Observational Study.

COVID-19治療薬の副作用は薬ごとに異なり、リアルタイム監視が重要

対象DB：FAERS,KAERS

14. Adverse event profile of albumin-bound paclitaxel: a real-world pharmacovigilance analysis.

アブラキサンの副作用は血液・肝臓障害が多く、性別でリスクが異なる

対象DB：FAERS

15. A pharmacovigilance analysis of post-marketing safety of tezepelumab.

テゼペルマブの副作用は呼吸器系疾患が多い

対象DB：FAERS

16. Drug risks associated with sarcopenia: a real-world and GWAS study.

メトホルミン、アスピリン、アセトアミノフェンは薬剤性サルコペニアを引き起こす可能性あり

対象DB：FAERS

17. A Pharmacovigilance Study on Psychotropic Agent-Induced Urinary Retention Using the Japanese Adverse Drug Event Report Database.

精神薬は尿閉を引き起こす可能性があり、注意が必要

対象DB：JADER

18. The current state of Spina Bifida in low- and middle-income countries: where does Africa stand?

アフリカの低中所得国で脊髄披裂の課題解決が必要

対象DB：JADER

19. A Self-Reported Association between Temporomandibular Joint Disorders, Headaches, and Stress.

顎関節症は頭痛・ストレスと関連あり

対象DB：JADER

20. Signals of Possibly Persistent Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Disproportionality Analysis Using the EudraVigilance Database.

抗生物質の味覚・嗅覚・聴覚障害が未解決で報告頻度高

対象DB：EudraVigilance

21. Pharmacology of chlorphenamine and pseudoephedrine use in the common cold: a narrative review.

抗ヒスタミン薬は、血管収縮薬より風邪症状に有利

対象DB：EudraVigilance

22. Tapentadol: navigating the complexities of abuse, patient safety & regulatory measures.

インドでタペンタドールの乱用事例が報告され、規制強化が必要

対象DB：VigiBase

23. The impact of financial incentives promoting biosimilar products in oncology: A quasi-experimental study using administrative data.

日本の健康政策により、バイオシミラー処方が増加

対象DB：DPC

24. Time trends of outcome and treatment options for disseminated intravascular coagulation from 2010 to 2021 in Japan: A nationwide observational study.

DIC患者の院内死亡率は減少、抗凝固療法の使用減少

対象DB：DPC

25. Nationwide database study of postoperative sequelae and in-hospital mortality in super-elderly hip fracture patients.

90歳以上の股関節骨折患者は合併症と死亡リスクが高い

対象DB：DPC

26. Value-based reimbursement under the inpatient prospective payment system in Japan: a review of Japan's diagnosis procedure combination/per-diem payment system.

FEC II調整は地域や病院特性で異なる

対象DB：DPC

27. Trajectory Patterns of Three Lifestyle Behaviors and Subsequent Health Conditions in Japanese Adults: A Retrospective Longitudinal Study Using a Health Checkup Database.

運動と禁煙・節酒が健康維持に重要

対象DB：JMDC

28. Real-world study on disease burden and current clinical practice of hospital-acquired pneumonia in Japan.

日本のHAP患者、高齢者多く、死亡率22%

対象DB：MDV

29. Investigating the Potential Short-term Adverse Effects of the Quadrivalent Human Papillomavirus Vaccine: A Novel Regression Discontinuity Analysis.

HPVワクチン接種、副作用リスク増加の証拠なし

対象DB：CPRD

30. Clinical Burden and Health Care Resource Utilization Associated With Managing Sickle Cell Disease With Recurrent Vaso-occlusive Crises in England.

鎌状赤血球症、VOCs多発で死亡率と医療負担増加

対象DB：CPRD

31. The application study of harmonization code in medical device adverse event reporting.

医療機器有害事象のコード選択に多様性確認

対象DB：KAERS

32. Diffuse lung diseases ascribed to drugs: a nationwide observational study over 37 years using the French pharmacovigilance database.

薬剤性肺疾患、重篤で致死例あり、早期診断重要

対象DB：FPVD

33. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial.

コンシズマブ、出血抑制効果確認、安全性も評価

対象DB：CVAR

34. Trends in the incidence of young-adult-onset diabetes by diabetes type: a multi-national population-based study from an international diabetes consortium.

若年成人の糖尿病発症率、地域で異なり増加傾向も

対象DB：DeSC